Medical Devices & Equipment - Injectable Drug Delivery Systems
Strategic Profile
Ypsomed intends to focus on expanding its leading position in Delivery Systems and is examining strategic options for the Diabetes Care business area. The company is investing CHF 1.5 billion to nearly triple capacity to 1 billion devices by early next decade, with new sites in Germany, China, and the U.S. This aggressive expansion capitalizes on booming demand for autoinjectors as major pharma scales obesity and diabetes treatments.
Cyborg Score Rationale
Trailing twelve month revenue for Ypsomed is $925M, with 2024 revenue of 748.87 million, an increase of 36.54% compared to the previous year. Strong balance sheet with equity ratio at 67%, net debt/EBITDA at 0.3x, and operating cash flow above CHF 140 million supports confident execution of massive capex plans. Market tailwinds from obesity medication and diabetes innovation are structural, not cyclical.
Top Insights
Capacity expansion of CHF 1.5 billion to reach 1 billion devices by early next decade across Germany, China, and U.S. sites demonstrates conviction in multi-year demand surge
Recent collaborations with large pharma companies to enhance integration of drug delivery devices with new biologic therapies underline Ypsomed's pivotal role in the self-medication landscape
Midterm targets include CHF 900 million–1.2 billion in sales, CHF 280–340 million EBIT, and EBIT margins above 30% signal ambitious yet disciplined growth trajectory
SHL Medical is a competitor of Ypsomed, but Ypsomed's scale, R&D depth, and pharma partnerships provide defensible competitive moat
Named Competitors
SHL Medical — Competitor in precision injection systems
Recent Developments
(December 2025) Ypsomed completed corporate asset purchase for real estate in Holly Springs, North Carolina, supporting North American expansion
(2024) Ypsomed and MTD signed agreement on transfer of pen needle and blood glucose monitoring businesses to MTD to ensure long-term unique pen needle supply and focus diabetes care on mylife Loop insulin pump innovation
(2024) Ypsomed announced investment of over CHF 100 million over four years in expansion of autoinjector capacities at Solothurn site
Open the full interactive Ypsomed Holding AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.